Multi-Center Evaluation of Opioid Administration or Prescription in Pediatric Oncology Patients Using the OMOP CDM

IF 3.5 2区医学 Q2 ONCOLOGY

Cancer Medicine Pub Date : 2026-09-28 DOI:10.1002/cam4.72310

Yuqing Feng, Martin Yi, Catherine C. Aftandilian, Melissa P. Beauchemin, Christine Cunningham, David DeStephano, Rhea K. Khurana, Emily Larimer, Jennifer Oberg, Benjamin L. May, Keith Morse, Karthik Natarajan, David Noyd, Victoria Soucek, Yujie Chen, Adam Yan, Lin Lawrence Guo, Lillian Sung

{"title":"Multi-Center Evaluation of Opioid Administration or Prescription in Pediatric Oncology Patients Using the OMOP CDM","authors":"Yuqing Feng, Martin Yi, Catherine C. Aftandilian, Melissa P. Beauchemin, Christine Cunningham, David DeStephano, Rhea K. Khurana, Emily Larimer, Jennifer Oberg, Benjamin L. May, Keith Morse, Karthik Natarajan, David Noyd, Victoria Soucek, Yujie Chen, Adam Yan, Lin Lawrence Guo, Lillian Sung","doi":"10.1002/cam4.72310","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Purpose</h3>\n \n <p>Opioid use in pediatric oncology is poorly characterized. The primary objective was to describe opioid administration or prescription patterns in pediatric oncology patients.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>In this multi-center retrospective study conducted across three sites, we included patients aged 0–19 years with a malignant neoplastic disease who received their first chemotherapy between January 2019 and March 2024. Data were extracted from each site's Observational Medical Outcomes Partnership Common Data Model. We described patient characteristics based on: (1) first opioid administration or prescription, overall and for each specific opioid; and (2) all opioid administrations or prescriptions, overall and for each specific opioid. We also evaluated variability in opioid and naloxone use.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Of 2903 pediatric patients with cancer, 2707 (93.2%) were administered or prescribed at least one opioid. Among these patients, fentanyl was the most common (92.4%), followed by morphine (68.7%), hydromorphone (55.3%), and oxycodone (38.6%). Across centers, the proportion of patients receiving fentanyl ranged from 90.9% to 94.9%, morphine from 34.0% to 89.2%, oxycodone from 0.9% to 76.1%, and naloxone from 2.4% to 29.5%. Overall, 10.9% were administered or prescribed naloxone, but among 169 methadone patients, 43.5% were administered or prescribed it. Of the 153,849 total opioid administrations or prescriptions, 22.4% occurred more than 12 months after initiating chemotherapy.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>Among pediatric patients with cancer who receive chemotherapy, 93.2% were administered or prescribed at least one opioid; fentanyl was the most common. There was heterogeneity in opioid choice and naloxone use across sites. These findings lay preliminary groundwork for understanding opioid use patterns and identifying potential areas for practice improvement in pediatric oncology.</p>\n </section>\n </div>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":"15 10","pages":""},"PeriodicalIF":3.5000,"publicationDate":"2026-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13620299/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Medicine","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cam4.72310","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose

Opioid use in pediatric oncology is poorly characterized. The primary objective was to describe opioid administration or prescription patterns in pediatric oncology patients.

Methods

In this multi-center retrospective study conducted across three sites, we included patients aged 0–19 years with a malignant neoplastic disease who received their first chemotherapy between January 2019 and March 2024. Data were extracted from each site's Observational Medical Outcomes Partnership Common Data Model. We described patient characteristics based on: (1) first opioid administration or prescription, overall and for each specific opioid; and (2) all opioid administrations or prescriptions, overall and for each specific opioid. We also evaluated variability in opioid and naloxone use.

Results

Of 2903 pediatric patients with cancer, 2707 (93.2%) were administered or prescribed at least one opioid. Among these patients, fentanyl was the most common (92.4%), followed by morphine (68.7%), hydromorphone (55.3%), and oxycodone (38.6%). Across centers, the proportion of patients receiving fentanyl ranged from 90.9% to 94.9%, morphine from 34.0% to 89.2%, oxycodone from 0.9% to 76.1%, and naloxone from 2.4% to 29.5%. Overall, 10.9% were administered or prescribed naloxone, but among 169 methadone patients, 43.5% were administered or prescribed it. Of the 153,849 total opioid administrations or prescriptions, 22.4% occurred more than 12 months after initiating chemotherapy.

Conclusions

Among pediatric patients with cancer who receive chemotherapy, 93.2% were administered or prescribed at least one opioid; fentanyl was the most common. There was heterogeneity in opioid choice and naloxone use across sites. These findings lay preliminary groundwork for understanding opioid use patterns and identifying potential areas for practice improvement in pediatric oncology.

查看原文本刊更多论文

使用OMOP CDM对小儿肿瘤患者阿片类药物给药或处方的多中心评价。

目的：阿片类药物在儿科肿瘤学中的应用尚不明确。主要目的是描述小儿肿瘤患者的阿片类药物给药或处方模式。方法：在这项跨三个地点进行的多中心回顾性研究中，我们纳入了年龄为0-19岁的恶性肿瘤患者，他们在2019年1月至2024年3月期间接受了第一次化疗。数据从每个站点的观察性医疗结果伙伴关系公共数据模型中提取。我们对患者特征的描述基于：(1)首次阿片类药物给药或处方，总体和每种特定阿片类药物；(2)所有阿片类药物管理或处方，总体和每种特定阿片类药物。我们还评估了阿片类药物和纳洛酮使用的变异性。结果：在2903例儿童癌症患者中，2707例（93.2%）使用或处方了至少一种阿片类药物。其中芬太尼最常见（92.4%），其次是吗啡（68.7%）、氢吗啡酮（55.3%）和羟考酮（38.6%）。各中心接受芬太尼治疗的患者比例为90.9% ~ 94.9%，吗啡为34.0% ~ 89.2%，羟考酮为0.9% ~ 76.1%，纳洛酮为2.4% ~ 29.5%。总体而言，10.9%的患者服用或处方纳洛酮，但在169例美沙酮患者中，43.5%的患者服用或处方纳洛酮。在153,849次阿片类药物给药或处方中，22.4%发生在化疗开始后12个月以上。结论：在接受化疗的儿科癌症患者中，93.2%的患者使用或处方了至少一种阿片类药物；芬太尼是最常见的。阿片类药物的选择和纳洛酮的使用存在异质性。这些发现为理解阿片类药物使用模式和确定儿科肿瘤学实践改进的潜在领域奠定了初步基础。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer Medicine ONCOLOGY-

CiteScore

5.50

自引率

2.50%

发文量

907

审稿时长

19 weeks

期刊介绍： Cancer Medicine is a peer-reviewed, open access, interdisciplinary journal providing rapid publication of research from global biomedical researchers across the cancer sciences. The journal will consider submissions from all oncologic specialties, including, but not limited to, the following areas: Clinical Cancer Research Translational research ∙ clinical trials ∙ chemotherapy ∙ radiation therapy ∙ surgical therapy ∙ clinical observations ∙ clinical guidelines ∙ genetic consultation ∙ ethical considerations Cancer Biology: Molecular biology ∙ cellular biology ∙ molecular genetics ∙ genomics ∙ immunology ∙ epigenetics ∙ metabolic studies ∙ proteomics ∙ cytopathology ∙ carcinogenesis ∙ drug discovery and delivery. Cancer Prevention: Behavioral science ∙ psychosocial studies ∙ screening ∙ nutrition ∙ epidemiology and prevention ∙ community outreach. Bioinformatics: Gene expressions profiles ∙ gene regulation networks ∙ genome bioinformatics ∙ pathwayanalysis ∙ prognostic biomarkers. Cancer Medicine publishes original research articles, systematic reviews, meta-analyses, and research methods papers, along with invited editorials and commentaries. Original research papers must report well-conducted research with conclusions supported by the data presented in the paper.